Author:
He Jing,Cui Long,Zeng Yu,Wang Guangqiang,Zhou Ping,Yang Yuanyuan,Ji Lei,Zhao Yanyan,Chen Jiwu,Wang Zhuo,Shi Tieliu,Zhang Pei,Chen Rui,Li Xiaotao
Abstract
Abstract
Background
Recent studies suggest a role of the proteasome activator, REGγ, in cancer progression. Since there are limited numbers of known REGγ targets, it is not known which cancers and pathways are associated with REGγ.
Methods
REGγ protein expressions in four different cancers were investigated by immunohistochemistry (IHC) analysis. Following NCBI Gene Expression Omnibus (GEO) database search, microarray platform validation, differential expressions of REGγ in corresponding cancers were statistically analyzed. Genes highly correlated with REGγ were defined based on Pearson's correlation coefficient. Functional links were estimated by Ingenuity Core analysis. Finally, validation was performed by RT-PCR analysis in established cancer cell lines and IHC in human colon cancer tissues
Results
Here, we demonstrate overexpression of REGγ in four different cancer types by micro-tissue array analysis. Using meta-analysis of publicly available microarray databases and biological studies, we verified elevated REGγ gene expression in the four types of cancers and identified genes significantly correlated with REGγ expression, including genes in p53, Myc pathways, and multiple other cancer-related pathways. The predicted correlations were largely consistent with quantitative RT-PCR analysis.
Conclusions
This study provides us novel insights in REGγ gene expression profiles and its link to multiple cancer-related pathways in cancers. Our results indicate potentially important pathogenic roles of REGγ in multiple cancer types and implicate REGγ as a putative cancer marker.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference33 articles.
1. Mao I, Liu J, Li X, Luo H: REGgamma, a proteasome activator and beyond. Cellular Mol Life Sci. 2008, 65: 3971-3980. 10.1007/s00018-008-8291-z.
2. Okamura T, Taniguchi S, Ohkura T, Yoshida A, Shimizu H, Hisatome I, Shiqemasa C: Abnormally high expression of proteasome activator-gamma in thyroid neoplasm. JCEM. 2003, 88: 1374-1383.
3. Markus R: Identification of PSME3 as a Novel Serum Tumor Marker for Colorectal Cancer by combing two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol Cellular Proteomics. 2006, 1: 2092-2101.
4. Jia HL, Ye QH, Qin LX, Budhu A, Forgues M, Chen Y, Liu YK, Sun HC, Wang L, Lu HZ, et al: Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res. 2007, 13: 1133-1139. 10.1158/1078-0432.CCR-06-1025.
5. Jiang X, Tan J, Li J, Kivimae S, Yang X, Zhuang L, Lee PL, Chan MT, Stanton LW, Liu ET, et al: DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell. 2008, 13: 529-541. 10.1016/j.ccr.2008.04.019.
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献